Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

Vertex Pharmaceuticals continues to see patients with sickle ... "People believe in the promise of gene therapy," said Priya ...

The Israeli spyware company blacklisted over human rights concerns has hired the firm to provide strategic advice on cyber policy issues.

DOGE has turned its focus to the government's contracts with consulting firms. Federal agencies have until March 7 to submit reviews of their existing contracts with 10 major firms. The government ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The global Tax Tech Market will grow from USD 18.53 billion in 2024 to USD 36.72 billion by 2030 at a compounded annual growth rate (CAGR) ...

LAW FIRM PRESSURE CAMPAIGN HITS CONGRESS: President Donald Trump’s retribution tour against Big Law has arrived on Capitol Hill, Dasha Burns, Daniel and I report. An email circulated by a high ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Vertex Pharmaceuticals continues to see patients ... biopharmaceuticals sector leader at Boston Consulting Group. "Investment is dropping because the overall economics and policy landscape has ...